A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well known. We prospectively compared the outcomes...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Thépot, Sylvain, Ben Abdelali, Raouf, Chevret, Sylvie, Renneville, Aline, Beyne-Rauzy, Odile, Prébet, Thomas, Park, Sophie, Stamatoullas, Aspasia, Guerci-Bresler, Agnes, Cheze, Stéphane, Tertian, Gérard, Choufi, Bachra, Legros, Laurence, Bastié, Jean Noel, Delaunay, Jacques, Chaury, Marie Pierre, Sanhes, Laurence, Wattel, Eric, Dreyfus, Francois, Vey, Norbert, Chermat, Fatiha, Preudhomme, Claude, Fenaux, Pierre, Gardin, Claude
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2016
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967570/
https://ncbi.nlm.nih.gov/pubmed/27229713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.140988
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires